DermProducts

Nine percent revenue growth driven by higher volume continues strong
trend for the year.
-- 21 percent of Q2 revenue invested in R&D to advance pipeline of nearly
70 potential new medicines in clinical development.
-- Ongoing cost-containment efforts support double-digit growth in
operating income.
-- Q2 earnings per share grow to $1.22 (reported), or $1.24 (non-GAAP).
-- 2010 earnings per share guidance range raised to $4.44 to $4.59
(reported), or $4.50 to $4.65 (non-GAAP), following strong first-half
results.

MELA Sciences, Inc. announced today that the U.S. Food and Drug
Administration (FDA) has informed the company that it is moving the
General and Plastic Surgery Devices Panel for MelaFind®, which was
originally scheduled for August 26, 2010, to November 2010.

"The FDA informed us today that more time is required to arrange the
meeting," said Joseph V. Gulfo, MD, President & CEO. "We are ready to
go now, and we will maintain our state of preparedness. This is
untimely, however, it is not totally surprising given that the

Up until approximately a decade ago, vein stripping was the only means of eradicating unsightly varicose veins. This method involved making an incision in the leg, and using a hooked wire to pull the affected vein out of the body. The invasiveness of vein stripping often resulted in an overnight hospital stay and considerable restriction of physical activity for up to a month. However, since the laser surgery method first became FDA approved ten years ago, it has come a long way in allowing for more convenient, painless and rapid removal of problematic veins.

Syneron Medical Ltd., a leading medical aesthetic device innovator,
reports today the growing popularity of eMatrix™ amongst physicians
worldwide in safely and effectively treating all skin tones. Historically,
physicians have struggled to find treatments that could deliver significant
noticeable results for all skin tones while remaining gentle enough
to prevent adverse events. The most common dermatological concerns
for patients with darker skin tones, which include African-American,
Asian, Hispanic, East Indian and other darker skin type patients, are